CollPlant Biotechnologies (NASDAQ:CLGN) Posts Earnings Results, Misses Expectations By $0.65 EPS

CollPlant Biotechnologies (NASDAQ:CLGN) announced its quarterly earnings data on Wednesday. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.65), Zacks reports. The business had revenue of $0.08 million during the quarter, compared to the consensus estimate of $16.52 million. CollPlant Biotechnologies had a negative return on equity of 94.08% and a negative net margin of 541.34%.

CollPlant Biotechnologies Price Performance

Shares of CollPlant Biotechnologies stock opened at $2.23 on Friday. The business has a fifty day simple moving average of $2.30 and a two-hundred day simple moving average of $2.21. CollPlant Biotechnologies has a 1 year low of $1.31 and a 1 year high of $4.98. The company has a market capitalization of $28.36 million, a price-to-earnings ratio of -1.97 and a beta of 1.38.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. D. Boral Capital reissued a “buy” rating and set a $12.00 price target on shares of CollPlant Biotechnologies in a research report on Monday, October 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CollPlant Biotechnologies in a research report on Wednesday, October 8th. Finally, HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of CollPlant Biotechnologies in a research report on Thursday, August 21st. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, CollPlant Biotechnologies has an average rating of “Hold” and a consensus target price of $11.50.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.